This study investigates the treatment of solid pseudopapillary tumor of the pancreas.
The focus of this study is to evaluate the safety and effectiveness of tamoxifen, an investigational medication, in managing advanced cases of this condition.
- Who can participate: Participants aged 14 to 80 years with advanced solid pseudopapillary tumor of the pancreas that is hormone receptor-positive may be eligible. They should have at least one measurable lesion and a life expectancy of at least one month.
- Study details: Participants will take tamoxifen orally and attend study visits. Some participants may receive a placebo, which is an inactive substance that looks like the investigational medicine but does not contain any medicine.